



May 22, 2020

**BSE Limited,**  
Department of Corporate Services,  
P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
**MUMBAI - 400 001.**

✓ **National Stock Exchange of India Ltd.,**  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**MUMBAI - 400 051.**

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30 of the SEBI  
(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Enclosed is a Press Release as regards receipt of U.S. FDA approval for the Company's Trientine Hydrochloride Capsules USP, 250 mg, to market a generic equivalent of Syprine® Capsules, 250 mg, of Bausch Health US, LLC.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

**For LUPIN LIMITED**

RAJVARDH  
AN VISHNU  
SATAM

Digitally signed by RAJVARDHAN VISHNU  
SATAM  
DN: cn=RA, o=Personal, postalCode=400062,  
st=Maharashtra,  
2.5.4.20=c158b4f61d95a59b73a093a4d19  
24623123a20f99a5a2a2a2f70709537387,  
serialNumber=d8ba0e0a8b79663a738aa  
2302a04f4a219772a0ba7a70f9a424771  
b2a, cn=RAJVARDHAN VISHNU SATAM  
Date: 2020.05.22 12:35:43 +05'30'

**R. V. SATAM**  
**COMPANY SECRETARY**  
**(ACS - 11973)**

Encl- : a/a.

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

## **Lupin Receives Approval for Trientine Hydrochloride Capsules USP**

**Mumbai, Baltimore, May 22, 2020:** Pharma major Lupin Limited (Lupin) announced that it has received approval for its Trientine Hydrochloride Capsules USP, 250 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Syprine® Capsules, 250 mg, of Bausch Health US, LLC. The product would be manufactured at Lupin's Nagpur (Unit 1) facility, India.

Trientine Hydrochloride Capsules USP, 250 mg, are indicated in the treatment of patients with Wilson's disease who are intolerant of penicillamine.

Trientine Hydrochloride Capsules USP (RLD: Syprine®) had an annual sales of approximately USD 86 million in the U.S. (IQVIA MAT March 2020).

### **About Lupin**

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions and in India by global revenues. The Company invests 9.6 % of its revenues on research and development.

Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit [www.lupin.com](http://www.lupin.com) for more information.

Follow us on Twitter: [www.twitter.com/LupinGlobal](https://www.twitter.com/LupinGlobal) | LinkedIn: [www.linkedin.com/company/lupin/](https://www.linkedin.com/company/lupin/)

Facebook: [www.facebook.com/LupinWorld/](https://www.facebook.com/LupinWorld/)

### **For further information or queries please contact –**

**Arvind Bothra**

Head – Investor Relations and Corporate Communications

Email: [arvindbothra@lupin.com](mailto:arvindbothra@lupin.com)

Tel: +91 22 6640 8237

**Manjira Sharma**

General Manager – Corporate Communications

Email: [manjirasharma@lupin.com](mailto:manjirasharma@lupin.com)

Tel: +91 22 6640 2532

***\*Safe Harbor Statement***

Syprine® is a registered trademark of Bausch Health Ireland Limited.